A235980 Share Price Performance
Recent A235980 News & Updates
No updates
MedPacto, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -414.88
- Gross Margin
- -13.92%
- Net Profit Margin
- -3,307.46%
- Debt/Equity Ratio
- 0%
MedPacto, Inc. Competitors
About A235980
- Founded
- n/a
- Employees
- 61
- CEO
- WebsiteView website
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -2.5%
- 3 Months: 19.7%
- 1 Year: 13.3%
- Year to Date: 27.4%
Over the last 7 days, the market has dropped 2.5%, driven by a pullback of 8.3% in the Financials sector. In the last year, the market is actually up 13%. Earnings are forecast to grow by 22% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading